CA2245863A1 - Pharmaceutical composition enabling to inhibit cancer metastasis formation containing n-acetyl-cysteine and doxorubicin - Google Patents

Pharmaceutical composition enabling to inhibit cancer metastasis formation containing n-acetyl-cysteine and doxorubicin Download PDF

Info

Publication number
CA2245863A1
CA2245863A1 CA002245863A CA2245863A CA2245863A1 CA 2245863 A1 CA2245863 A1 CA 2245863A1 CA 002245863 A CA002245863 A CA 002245863A CA 2245863 A CA2245863 A CA 2245863A CA 2245863 A1 CA2245863 A1 CA 2245863A1
Authority
CA
Canada
Prior art keywords
nac
dox
cysteine
doxorubicin
acetyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002245863A
Other languages
English (en)
French (fr)
Inventor
Silvio De Flora
Adriana Albini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zambon Group SpA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2245863A1 publication Critical patent/CA2245863A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
CA002245863A 1996-02-14 1997-02-12 Pharmaceutical composition enabling to inhibit cancer metastasis formation containing n-acetyl-cysteine and doxorubicin Abandoned CA2245863A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITM196A000277 1996-02-14
IT96MI000277A IT1282625B1 (it) 1996-02-14 1996-02-14 Composizione farmaceutica atta ad inibire la formazione di metastasi tumorali

Publications (1)

Publication Number Publication Date
CA2245863A1 true CA2245863A1 (en) 1997-08-21

Family

ID=11373264

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002245863A Abandoned CA2245863A1 (en) 1996-02-14 1997-02-12 Pharmaceutical composition enabling to inhibit cancer metastasis formation containing n-acetyl-cysteine and doxorubicin

Country Status (7)

Country Link
EP (1) EP0885006B1 (instruction)
JP (1) JP2000504704A (instruction)
AT (1) ATE273710T1 (instruction)
CA (1) CA2245863A1 (instruction)
DE (1) DE69730317D1 (instruction)
IT (1) IT1282625B1 (instruction)
WO (1) WO1997029759A1 (instruction)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
US20080200563A1 (en) * 2004-07-22 2008-08-21 Thiomatrix Forschungs- Und Beratungs- Gmbh Use of Compounds Containing Thiol Groups as Efflux Pump Inhibitors
CN101743020A (zh) 2007-05-16 2010-06-16 Ktb肿瘤研究有限责任公司 低粘度蒽环制剂
WO2011110838A2 (en) * 2010-03-08 2011-09-15 Procure Therapeutics Limited Differentiation factor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331648A (en) * 1979-12-05 1982-05-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services N-Acetyl-cysteine protects against cardiac damage from subsequently-administered cardio-toxic anthra-cycline in cancer therapy
US4873088A (en) * 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition

Also Published As

Publication number Publication date
EP0885006B1 (en) 2004-08-18
WO1997029759A1 (en) 1997-08-21
IT1282625B1 (it) 1998-03-31
DE69730317D1 (de) 2004-09-23
JP2000504704A (ja) 2000-04-18
ATE273710T1 (de) 2004-09-15
ITMI960277A1 (it) 1997-08-14
ITMI960277A0 (instruction) 1996-02-14
EP0885006A1 (en) 1998-12-23

Similar Documents

Publication Publication Date Title
Derendorf et al. Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra‐articular administration
Seaman et al. Natural killing in estrogen-treated mice responds poorly to poly I· C despite normal stimulation of circulating interferon
CZ290120B6 (cs) Sdruľená kompozice paclitaxelu, docetaxelu nebo jejich analogu
HUP0302021A2 (hu) Szteroid tartalmú stabilizált vizes szuszpenziók parenterális használathoz
NZ501160A (en) Subcutaneously injectable quinolone formulations with zinc or magnesium compounds and a co-solvent
DE102004063347A1 (de) Gebrauchsfertige Gemcitabinlösungen und Gemcitabinlösungskonzentrate
JP2023544310A (ja) プロバイオティクス成分の使用及びプロバイオティクス成分を含む医薬組成物
CA2245863A1 (en) Pharmaceutical composition enabling to inhibit cancer metastasis formation containing n-acetyl-cysteine and doxorubicin
CA1135188A (en) Oxytetracycline compositions
WO2008033041A1 (en) Cancer treatment
US6730664B1 (en) Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins
SK1782002A3 (en) Formulations for parenteral use of estramustine phosphate and albumin
EP0754037A1 (en) Methods of administering n-substituted benzamides or phenothiazines
US20250144111A1 (en) Taurolidine treatment for myc-expressing tumors in mammalian bodies
JP2003509355A (ja) 薬理学的特性が改善されたリン酸エストラムスチン塩の非経口的使用のための処方
JPWO2021151019A5 (instruction)
EP1465617B1 (en) Process for affecting neurologic progression
HUP0200547A2 (hu) Eljárás intravénás ösztramusztin-foszfát potencirozására szolgáló gyógyszerkészítmények előállítására
CN118436762A (zh) 替考拉宁在制备治疗雄激素性脱发药物中的应用
US20230330123A1 (en) A non-aqueous suspension of anticancer agent
EP0083673A1 (de) Erzeugnisse zur intravasalen Applikation von wasserlöslichen bzw. emulgierbaren antigenen Organextrakten
JP2005520806A (ja) がん治療を改善する併用療法におけるキナゾリノン化合物
ZA200201955B (en) Formulations for parenteral use of estramustine phosphate and albumin.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued